Clinical trial · no report yet · Phase 3
NCT02954874
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
- NCT02954874 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 6 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| YouTube | 4 | |
| Podcasts | 1 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Breast Carcinoma In Situ; Invasive Breast Carcinoma; Stage I Breast Cancer AJCC v7; Stage II Breast Cancer AJCC v6 and v7; Stage III Breast Cancer AJCC v7; Triple-Negative Breast Carcinoma
- Interventions
- Biospecimen Collection; Laboratory Biomarker Analysis; Patient Observation; Pembrolizumab; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy
- Arms
- Arm I (observation) · Experimental
- Arm II (pembrolizumab) · Experimental
- Enrollment
- 1,195
- Primary outcomes
- Invasive disease-free survival (IDFS)
- Severity of fatigue
- Physical function
- Sponsor
- National Cancer Institute (NCI)
- Start
- Jan 18, 2017
- Primary completion
- Aug 3, 2026
- Results posted
- No
- Registry record
- NCT02954874 · updated Aug 31, 2026